Last updated: February 25, 2026
What Is the Drug with NDC 70000-0061?
NDC 70000-0061 corresponds to Zolbetuximab, an experimental monoclonal antibody targeting Claudin 18.2. It is developed by Affimed and serve as an immunotherapy aimed at gastric and gastroesophageal cancers. Zolbetuximab has completed phase 2 trials and remains under review for regulatory approval; commercialization has not occurred.
Market Context and Competitive Landscape
Therapeutic Area Overview
- Indication: Gastric, gastroesophageal junction, and pancreatic cancers.
- Target Population: Estimated at 1.2 million new cases globally annually (GLOBOCAN, 2020).
- Standard of Care: Chemotherapy, immunotherapy with PD-1 inhibitors, and targeted therapy.
Key Competitors
| Drug Name |
Mechanism |
Approval Status |
Estimated Market Share (2023) |
Pricing (USD) per treatment cycle |
| Trastuzumab (Herceptin) |
HER2 monoclonal antibody |
Approved |
40% |
$2,600 |
| Pembrolizumab (Keytruda) |
PD-1 checkpoint inhibitor |
Approved |
20% |
$7,100 |
| Ramucirumab (Cyramza) |
VEGFR2 monoclonal antibody |
Approved |
15% |
$4,500 |
Zolbetuximab Market Entry Factors
- No approved therapies directly targeting Claudin 18.2.
- Clinical trial results showed promising efficacy, but no consensus on superiority over existing options.
- Regulatory paths may vary; U.S. FDA and EMA are reviewing data for potential approval.
Market Size and Revenue Projections
Assumptions
| Year |
Estimated Penetration |
Revenue Estimate (USD millions) |
| 2024 |
5% |
$50 |
| 2025 |
15% |
$150 |
| 2026 |
30% |
$300 |
| 2027 |
50% |
$500 |
Pricing Projections
- Initial price: $6,000 to $8,000 per cycle, aligned with immunotherapy pricing.
- Expected discounts for coverage negotiations and competitive market entry.
Revenue Estimate Calculation
Assuming an initial market size of 50,000 eligible patients in the United States and Europe combined in year 2024:
- Cost per treatment cycle: $7,000.
- Average treatments per patient per year: 6 cycles.
- Revenue per patient: $42,000.
Total potential revenue in 2024 at 5% market penetration:
| Metric |
Calculation |
Result |
| Patients (US + EU) |
50,000 × 0.05 |
2,500 |
| Total Revenue |
2,500 × $42,000 |
$105 million |
Projected growth aligns with increased approval and broader geographic access.
Price Development Factors
- Regulatory approval increases pricing flexibility.
- Entry of biosimilars or generics, if applicable, depresses prices.
- Price negotiations with payers impact final outpatient costs.
Risks and Market Barriers
- Clinical trial outcomes: Negative or inconclusive results deter adoption.
- Regulatory delays or rejections lower anticipated market size.
- Competitive dynamics: Market incumbents may launch similar or superior therapies.
Summary
Zolbetuximab remains in late-stage development with potential for commercial launch within 1–2 years depending on regulatory review completion. Market size hinges on Claudin 18.2 expression levels and the development of competing therapies. Revenue projections for 2024 start around $100 million annually in the US and Europe, with potential for growth to over $500 million by 2027 if approval and adoption accelerate.
Key Takeaways
- No current FDA or EMA approval; commercialization remains pending.
- Early market estimates place revenue potential at approximately $100 million in the first year post-launch.
- Pricing is expected around $7,000 per treatment cycle, with potential discounts.
- Competition from existing targeted and immunotherapies significantly influences market penetration.
- Market risk factors include regulatory success, clinical efficacy, and competitive responses.
FAQs
1. When might Zolbetuximab reach the market?
Likely within 1–2 years if ongoing regulatory reviews are successful.
2. What factors could affect its future pricing?
Regulatory approval, competition, reimbursement negotiations, and clinical efficacy.
3. Who are the primary competitors?
Existing targeted therapies such as trastuzumab, and immunotherapies like pembrolizumab.
4. What is the size of the eligible patient population?
Approximately 50,000 in the US and EU combined annually, with potential growth.
5. How does Zolbetuximab’s mechanism differ from other therapies?
It targets Claudin 18.2, a protein overexpressed in gastric cancers, which is a novel approach compared to HER2 or PD-1 targeting.
Citations
[1] GLOBOCAN. (2020). Estimated cancer incidences worldwide. IARC.
[2] Market data sources: IQVIA, Medi-Span.
[3] Clinical trial outcomes: ClinicalTrials.gov.
